...
首页> 外文期刊>Brain research >The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms.
【24h】

The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms.

机译:促肾上腺皮质激素释放因子(CRF)(1)受体拮抗剂CP154,526和DMP695抑制仓鼠昼夜活动节律的光诱导相进展。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The circadian activity of corticotropin releasing factor (CRF) and the hypothalamic-pituitary-adrenal axis is controlled by the master circadian pacemaker located in the hypothalamic suprachiasmatic nucleus. However, the reciprocal influence of CRF and the hypothalamic-pituitary-adrenal axis upon the circadian pacemaker is less well established. Therefore, in the present study, we tested two nonpeptidergic antagonists at CRF(1) receptors for their ability to modulate photic resetting of pacemaker time (phase). CP154,526 dose dependently and significantly inhibited light-induced phase advances in hamster circadian activity rhythms late in the subjective night by approximately 60% at a maximally effective dose of 20 mg/kg delivered intraperitoneally. Likewise, a further CRF(1) receptor antagonist, DMP695, inhibited phase advances by approximately 40% at a dose of 10 mg/kg. The attenuation of phase shifts by CP154,526 was specific to phase advances as light-induced phase delays of the circadian pacemaker achieved early in the subjective night were not affected by CP154,526 (20 mg/kg). We also tested one of the CRF(1) receptor antagonists for its potential ability to reset the pacemaker in the absence of light and found that CP154,526 did not elicit a nonphotic phase shifts in circadian activity rhythms at circadian times (CT) 2, 8, 14, 18, or 22. In conclusion, CRF(1) receptor antagonists selectively modulate the effect of light on the circadian pacemaker late at night. These novel data emphasize the suspected critical link between CRF and the hypothalamic-pituitary-adrenal axis, on the one hand, and stress (including stress caused by jet-lag) and depression on the other. These results also suggest that CRF(1) antagonists may not only improve affect but also counter the circadian disruption associated with depression and other stress-related disorders.
机译:促肾上腺皮质激素释放因子(CRF)和下丘脑-垂体-肾上腺轴的昼夜活动由位于下丘脑上眼睑上核的昼夜节律起搏器控制。但是,CRF和下丘脑-垂体-肾上腺轴对昼夜节律起搏器的相互影响尚不明确。因此,在本研究中,我们测试了两种非肽能拮抗剂在CRF(1)受体上的调节起搏器时间(阶段)的光复性的能力。 CP154,526剂量依赖性地并显着抑制腹膜内递送的最大有效剂量为20 mg / kg的主观夜间晚期仓鼠昼夜活动节律中光诱导的相进展。同样,另一种CRF(1)受体拮抗剂DMP695在10 mg / kg的剂量下可抑制相进展约40%。 CP154,526对相移的衰减特定于相位超前,因为在主观夜晚较早时实现的昼夜节律起搏器的光诱导相位延迟不受CP154,526(20 mg / kg)的影响。我们还测试了一种CRF(1)受体拮抗剂在无光情况下复位起搏器的潜在能力,发现CP154,526在昼夜节律(CT)2时,昼夜节律活动节律未引起非光相移。 8、14、18或22。总之,CRF(1)受体拮抗剂在深夜选择性地调节光对昼夜节律起搏器的影响。这些新颖的数据一方面强调了CRF与下丘脑-垂体-肾上腺轴之间的可疑的关键联系,另一方面强调了压力(包括时差引起的压力)和抑郁症。这些结果还表明,CRF(1)拮抗剂不仅可以改善情绪,还可以对抗与抑郁症和其他与压力有关的疾病相关的昼夜节律紊乱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号